373:2125-2135 [PubMed: 19501900] 105
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, Andreasen AH, Jensen CB, DeFronzo RA
While the price of $149 for the starting dose is lower than what the companies currently offer for the injectable drugs, that price is only for the initial, lowest dose
GLP-1 receptor agonist therapy and reduced incidence of rheumatic diseases: A propensity score-matched cohort study
Finally, the ability of GLP-1(2836) to decrease cleaved caspase-3 activation suggests that the agent prevents apoptosis (Figure 3E)
I guess, we (humanity) prefer to live in the "disinformation age," instead